|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1999; 33:924-931 © 1999 by the American College of Cardiology Foundation |
a Heart and Lung Transplant Unit, St. Vincent’s Hospital, Sydney, Australia
Manuscript received May 6, 1998; revised manuscript received October 23, 1998, accepted December 15, 1998.
Reprint requests and correspondence: Associate Professor Peter Macdonald, Heart & Lung Transplant Unit, St. Vincent’s Hospital, Darlinghurst, NSW, 2010 Australia
pmacdonald{at}stvincents.com.au
OBJECTIVES
The purpose of this study was to assess the tolerability and efficacy of carvedilol in patients with New York Heart Association (NYHA) functional class IV symptoms.
BACKGROUND
Carvedilol, a nonselective beta-adrenergic blocking drug with alpha-adrenergic blocking and antioxidant properties, has been shown to improve left ventricular function and clinical outcome in patients with mild to moderate chronic heart failure.
METHODS
We retrospectively analyzed the outcomes of 230 patients with heart failure treated with carvedilol who were stratified according to baseline functional class: 63 patients were NYHA class IV and 167 were NYHA class I, II or III. Carvedilol was commenced at 3.125 mg b.i.d. and titrated to 25 mg b.i.d. as tolerated. Patients with class IV symptoms were older (p = 0.03), had lower left ventricular fractional shortening (p < 0.001), had lower six-min walk distance (p < 0.001) and were receiving more heart failure medications at baseline compared with less symptomatic patients.
RESULTS
Nonfatal adverse events while taking carvedilol occurred more frequently in class IV patients (43% vs. 24%, p < 0.0001), and more often resulted in permanent withdrawal of the drug (25% vs. 13%, p < 0.01). Thirty-seven (59%) patients who were NYHA class IV at baseline had improved by one or more functional class at 3 months, 8 (13%) were unchanged and 18 (29%) had deteriorated or died. Among the less symptomatic group, 62 (37%) patients had improved their NYHA status at 3 months, 73 (44%) were unchanged and 32 (19%) had deteriorated or died. The differences in symptomatic outcome at three months between the two groups were statistically significant (p = 0.001, chi-square analysis). Both groups demonstrated similar significant improvements in left ventricular dimensions and systolic function.
CONCLUSIONS
Patients with chronic NYHA class IV heart failure are more likely to develop adverse events during initiation and dose titration when compared with less symptomatic patients but are more likely to show symptomatic improvement in the long term. We conclude that carvedilol is a useful adjunctive therapy for patients with NYHA class IV heart failure; however, they require close observation during initiation and titration of the drug.
| ||||||||||||||
This article has been cited by other articles:
|
|
 |
|
  T. H. Le Jemtel, M. Padeletti, and S. Jelic Diagnostic and Therapeutic Challenges in Patients With Coexistent Chronic Obstructive Pulmonary Disease and Chronic Heart Failure J. Am. Coll. Cardiol., January 16, 2007; 49(2): 171 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Patient n plus 1 Can. Med. Assoc. J., June 7, 2005; 172(12): 1525 - 1525. [Full Text] [PDF]
|
|
|
|
|
|
Patient n plus 1 Can. Med. Assoc. J., June 7, 2005; 172(12): 1527 - 1527. [Full Text] [PDF]
|
|
|
|
|
|
T. E. Sirak, S. Jelic, and T. H. Le Jemtel Therapeutic update: Non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure J. Am. Coll. Cardiol., August 4, 2004; 44(3): 497 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R H Arnold, E Kotlyar, C Hayward, A M Keogh, and P S Macdonald Relation between heart rate, heart rhythm, and reverse left ventricular remodelling in response to carvedilol in patients with chronic heart failure: a single centre, observational study Heart, March 1, 2003; 89(3): 293 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Metra, S. Nodari, A. D'Aloia, C. Muneretto, A. D. Robertson, M. R. Bristow, and L. Dei Cas Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol J. Am. Coll. Cardiol., October 2, 2002; 40(7): 1248 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Capomolla, G. Pinna, O. Febo, A. Caporotondi, G. Guazzotti, M. T. La Rovere, M. Gnemmi, A. Mortara, R. Maestri, and F. Cobelli Echo-Doppler mitral flow monitoring: an operative tool to evaluate day-to-day tolerance to and effectiveness of beta-adrenergic blocking agent therapy in patients with chronic heart failure J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1675 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Popovic, M. Miric, A.N. Neskovic, J. Vasiljevic, P. Otasevic, M. Zarkovic, M. Bojic, and S. Gradinac Functional capacity late after partial left ventriculectomy: relation to ventricular geometry and performance Eur. J. Cardiothorac. Surg., January 1, 2001; 19(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Lowes, M. Higginbotham, L. Petrovich, M. A. DeWood, M. A. Greenberg, P. S. Rahko, G. W. Dec, T. H. LeJemtel, R. L. Roden, M. M. Schleman, et al. Low-dose enoximone improves exercise capacity in chronic heart failure J. Am. Coll. Cardiol., August 1, 2000; 36(2): 501 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Romeo, D. Li, M. Shi, and J. L Mehta Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway Cardiovasc Res, February 1, 2000; 45(3): 788 - 794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Hoffman Carvedilol in class IV heart failure J. Am. Coll. Cardiol., December 1, 1999; 34(7): 2149 - 2149. [Full Text] [PDF]
|
|
|
|
|
|
P. Macdonald Reply J. Am. Coll. Cardiol., December 1, 1999; 34(7): 2149 - 2150. [Full Text] [PDF]
|
|
|
|
 |
|
 Carvedilol Beneficial for Class IV CHF Patients Journal Watch (General), March 30, 1999; 1999(330): 1 - 1. [Full Text]
|
|
|
|
 |
|
 S. S. Gottlieb, M. L. Fisher, J. Kjekshus, P. Deedwania, L. Gullestad, J. Vitovec, and J. Wikstrand Tolerability of {beta}-Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) Circulation, March 12, 2002; 105(10): 1182 - 1188. [Abstract] [Full Text] [PDF]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
